Global Community

ChargePoint (CHPT) Investment Thesis – Long-Term Outlook ChargePoint is one of the most established names in the EV charging ecosystem, with a strong footprint across Level 2 commercial and fleet infrastructure. While it doesn’t focus heavily on DC fast charging like some peers, its strategy emphasizes widespread workplace, multi-unit dwelling, and fleet solutions—crucial segments in an electrifying economy.Read more

The Cheesecake Factory is a stock that I believe most people do not understand it's actual potential; or really what makes this stock so attractive for long term growth. Here is a brief description of the company according to Benzinga: "Cheesecake Factory Inc owns and operates restaurants in the United States and Canada under brands that include The Cheesecake Factory, North Italia, and a collection within the Fox Restaurants Concepts subsidiary.Read more

A Deeper Look at Frencken Group: Sector, Earnings & Outlook Thinking about investing in a company that is a key player behind the scenes in the technology world? Frencken Group might be on your radar.Read more

This analysis concludes that Exxon Mobil (XOM) represents a compelling investment opportunity, with a fair value of $132.00 per share, implying a 17.5% upside from the current price of $112.32. The BUY recommendation is not based on a speculative bet on higher oil prices, but on the company's fundamental transformation, operational excellence, and disciplined capital allocation that is expected to generate sustainable, industry-leading returns.Read more

Zegona – Key Notes for Monitoring 1. Main thesis: Zegona acquired Vodafone Spain (EV €5.0 B) with very little cash outlay thanks to debt financing and €900 M in Redeemable Preference Shares (RPS) issued to Vodafone via EJLSHM Funding Ltd.Read more

1. Catalysts Evenamide (Schizophrenia Add-On Therapy): The key growth catalyst for Newron is Evenamide, a novel glutamate-modulating drug in Phase III development for treatment-resistant schizophrenia (TRS).Read more

DFC based on: Date: August 28, 2025 Forecast Horizon : 5.0 years ## Weighted Average Cost of Capital (WACC) - WACC Value : 0.0296 - Calculation Details : - Equity Market Value : 251,279,184.0 - Debt Market Value : 1,468,357.0 - Total Capital : 252,747,541.0 - Cost of Equity (CAPM) : 0.0292 - Cost of Debt : 0.1276 - Tax Rate : 30.95% ## Capital Asset Pricing Model (CAPM) - Risk-Free Rate : 0.0180 - Beta : 0.41 - Equity Risk Premium (ERP) : 0.0274 - CAPM Formula : Risk-free rate + Beta × ERP - CAPM Value : 0.0292 ## Cost of Debt - Interest Expense : 187,409.0 - Debt Market Value : 1,468,357.0 - Cost of Debt Formula : Interest Expense / Debt Market Value - Cost of Debt Value : 0.1276 ## Growth Model Analysis - Initial Growth Rate : 27.02% - Number of Periods (n) : 5.0 - Terminal Growth Rate : 2.00% ## WACC Data Table | Metric | Value | |:---------------------|-----------------:| | initial FCFF | 1.46232e+07 | | initial growth rate | 0.270176 | | equity market value | 2.51279e+08 | | debt market value | 1.46836e+06 | | tax rate | 0.309485 | | Risk-free rate | 0.018 | | beta | 0.41 | | ERP | 0.0274349 | | terminal growth rate | 0.02 | | forecast horizon | 5 | | Interest expense | 187409 | | number of shares | 4.05289e+08 | ## DCF Fair Value Estimate - Estimated Fair Bear Value: 6.107 - Estimated Fair Base Value: 7.499 - Estimated Fair Bull Value: 11.320 - Expected Value of PERT Distribution: 7.904Read more

Hipages appears to be at a significant turning point, showing strong signs of operational and financial health after a period of strategic change. The key takeaway from the FY25 results is the successful execution of its transition from a simple marketplace to a more integrated Software-as-a-Service (SaaS) platform, which is now yielding positive results.Read more

Catalysts AL001 : a novel lithium formulation targeting Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder (MDD), and PTSD. Phase II studies show promising safety/efficacy, with trials ongoing as of 2025.Read more